CORMEDIX INC. Accumulated Other Comprehensive Income
CORMEDIX INC. (CRMD) had Accumulated Other Comprehensive Income of $2.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-13
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $2.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $2.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $3.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $87.64K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax | Accumulated Other Comprehensive Income (Loss), Net of Tax as first filed |
|---|---|---|
| 2026-06-30 | $2.00K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $2.00K 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $3.00K 10-Q · filed 2026-08-13 | |
| 2025-09-30 | $87.64K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $79.44K 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $84.56K 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $91.00K 10-K · filed 2026-03-05 | $90.65K 10-K · filed 2025-03-25 |
| 2024-09-30 | $89.12K 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $85.73K 10-Q · filed 2024-08-14 | |
| 2024-03-31 | $83.46K 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $94.11K 10-K · filed 2025-03-25 | |
| 2023-09-30 | $84.40K 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $90.70K 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $101.23K 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $82.74K 10-K · filed 2024-03-12 | |
| 2022-09-30 | $45.77K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $39.52K 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $49.92K 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $87.13K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $95.50K 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $99.18K 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $98.83K 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $102.01K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $99.66K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $105.59K 10-Q · filed 2020-08-10 | |
| 2020-03-31 | $90.74K 10-Q · filed 2020-05-11 | |
| 2019-12-31 | $97.26K 10-K · filed 2021-03-30 | |
| 2019-09-30 | $102.00K 10-Q · filed 2019-11-14 | |
| 2019-06-30 | $104.34K 10-Q · filed 2019-08-14 | |
| 2019-03-31 | $95.21K 10-Q · filed 2019-05-13 | |
| 2018-12-31 | $96.52K 10-K · filed 2020-03-16 | |
| 2018-09-30 | $91.00K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | $97.40K 10-Q · filed 2018-08-14 | |
| 2018-03-31 | $97.01K 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $98.43K 10-K · filed 2019-05-29 | |
| 2017-09-30 | $94.71K 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $96.68K 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $90.31K 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $81.19K 10-K · filed 2018-03-19 | |
| 2016-09-30 | $83.30K 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $90.14K 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $92.98K 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $62.13K 10-K · filed 2017-03-16 | |
| 2015-09-30 | $99.79K 10-Q · filed 2015-11-12 | |
| 2015-06-30 | $92.70K 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $101.78K 10-Q · filed 2015-05-07 | |
| 2014-12-31 | $98.97K 10-K · filed 2016-03-15 | |
| 2014-09-30 | $116.98K 10-Q · filed 2014-11-13 | |
| 2014-06-30 | -$1.34K 10-Q · filed 2014-08-14 | |
| 2014-03-31 | -$10.68K 10-Q · filed 2014-05-15 | |
| 2013-12-31 | -$9.32K 10-K · filed 2015-03-12 | |
| 2012-12-31 | $0.00 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |